Form 4: Elicio Therapeutics Director Acquires Stock Options

Director Carol Gail Ashe of Elicio Therapeutics acquired 4,100 stock options on November 21, 2024, which will vest on the earlier of November 21, 2025, or the next annual meeting.

Summary

• Carol Gail Ashe, a director at Elicio Therapeutics, acquired 4,100 stock options on November 21, 2024.
• The exercise price of these options is $5.12 per share.
• The options will vest and become exercisable in full on the earlier of November 21, 2025, or the next annual meeting of the company's stockholders after the grant date.
• Vesting is contingent upon Ms. Ashe continuing to provide services to the company through the vesting date.
• The options expire on November 21, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it aligns director interests with shareholders. It is not a major event, but it is a positive indicator of director engagement.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future performance.

Future Outlook

The stock options will vest on the earlier of November 21, 2025, or the next annual meeting of the company's stockholders after the grant date, subject to continued service.

Industry Context

This is a standard transaction for directors of publicly traded companies, often used as part of their compensation package and to align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, similar to companies like Moderna and BioNTech.
• The vesting schedule of one year or the next annual meeting is also typical, aligning with standard industry practices for incentivizing long-term commitment.
• The exercise price of $5.12 is specific to Elicio Therapeutics and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant could positively impact shareholder sentiment by demonstrating director commitment.

Key Dates

Keywords

stock options, director, Elicio Therapeutics, ELTX, insider trading, equity, vesting